200 related articles for article (PubMed ID: 38039376)
1. Structural principles of peptide-centric chimeric antigen receptor recognition guide therapeutic expansion.
Sun Y; Florio TJ; Gupta S; Young MC; Marshall QF; Garfinkle SE; Papadaki GF; Truong HV; Mycek E; Li P; Farrel A; Church NL; Jabar S; Beasley MD; Kiefel BR; Yarmarkovich M; Mallik L; Maris JM; Sgourakis NG
Sci Immunol; 2023 Dec; 8(90):eadj5792. PubMed ID: 38039376
[TBL] [Abstract][Full Text] [Related]
2. Structural principles of peptide-centric Chimeric Antigen Receptor recognition guide therapeutic expansion.
Sun Y; Florio TJ; Gupta S; Young MC; Marshall QF; Garfinkle SE; Papadaki GF; Truong HV; Mycek E; Li P; Farrel A; Church NL; Jabar S; Beasley MD; Kiefel BR; Yarmarkovich M; Mallik L; Maris JM; Sgourakis NG
bioRxiv; 2023 May; ():. PubMed ID: 37292750
[TBL] [Abstract][Full Text] [Related]
3. Targeting of intracellular oncoproteins with peptide-centric CARs.
Yarmarkovich M; Marshall QF; Warrington JM; Premaratne R; Farrel A; Groff D; Li W; di Marco M; Runbeck E; Truong H; Toor JS; Tripathi S; Nguyen S; Shen H; Noel T; Church NL; Weiner A; Kendsersky N; Martinez D; Weisberg R; Christie M; Eisenlohr L; Bosse KR; Dimitrov DS; Stevanovic S; Sgourakis NG; Kiefel BR; Maris JM
Nature; 2023 Nov; 623(7988):820-827. PubMed ID: 37938771
[TBL] [Abstract][Full Text] [Related]
4. Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs.
Yarmarkovich M; Marshall QF; Warrington JM; Premaratne R; Farrel A; Groff D; Li W; di Marco M; Runbeck E; Truong H; Toor JS; Tripathi S; Nguyen S; Shen H; Noel T; Church NL; Weiner A; Kendsersky N; Martinez D; Weisberg R; Christie M; Eisenlohr L; Bosse KR; Dimitrov DS; Stevanovic S; Sgourakis NG; Kiefel BR; Maris JM
Nature; 2021 Nov; 599(7885):477-484. PubMed ID: 34732890
[TBL] [Abstract][Full Text] [Related]
5. Decoupling peptide binding from T cell receptor recognition with engineered chimeric MHC-I molecules.
Papadaki GF; Ani O; Florio TJ; Young MC; Danon JN; Sun Y; Dersh D; Sgourakis NG
Front Immunol; 2023; 14():1116906. PubMed ID: 36761745
[TBL] [Abstract][Full Text] [Related]
6. Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens.
Hwang MS; Miller MS; Thirawatananond P; Douglass J; Wright KM; Hsiue EH; Mog BJ; Aytenfisu TY; Murphy MB; Aitana Azurmendi P; Skora AD; Pearlman AH; Paul S; DiNapoli SR; Konig MF; Bettegowda C; Pardoll DM; Papadopoulos N; Kinzler KW; Vogelstein B; Zhou S; Gabelli SB
Nat Commun; 2021 Sep; 12(1):5271. PubMed ID: 34489470
[TBL] [Abstract][Full Text] [Related]
7. Bispecific chimeric antigen receptors targeting the CD4 binding site and high-mannose Glycans of gp120 optimized for anti-human immunodeficiency virus potency and breadth with minimal immunogenicity.
Ghanem MH; Bolivar-Wagers S; Dey B; Hajduczki A; Vargas-Inchaustegui DA; Danielson DT; Bundoc V; Liu L; Berger EA
Cytotherapy; 2018 Mar; 20(3):407-419. PubMed ID: 29306566
[TBL] [Abstract][Full Text] [Related]
8. A major histocompatibility complex-peptide-restricted antibody and t cell receptor molecules recognize their target by distinct binding modes: crystal structure of human leukocyte antigen (HLA)-A1-MAGE-A1 in complex with FAB-HYB3.
Hülsmeyer M; Chames P; Hillig RC; Stanfield RL; Held G; Coulie PG; Alings C; Wille G; Saenger W; Uchanska-Ziegler B; Hoogenboom HR; Ziegler A
J Biol Chem; 2005 Jan; 280(4):2972-80. PubMed ID: 15537658
[TBL] [Abstract][Full Text] [Related]
9. Impact of scFv structure in chimeric antigen receptor on receptor expression efficiency and antigen recognition properties.
Fujiwara K; Masutani M; Tachibana M; Okada N
Biochem Biophys Res Commun; 2020 Jun; 527(2):350-357. PubMed ID: 32216966
[TBL] [Abstract][Full Text] [Related]
10. Inclusion of 4-1BB Costimulation Enhances Selectivity and Functionality of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells.
Starr R; Aguilar B; Gumber D; Maker M; Huard S; Wang D; Chang WC; Brito A; Chiu V; Ostberg JR; Badie B; Forman SJ; Alizadeh D; Wang LD; Brown CE
Cancer Res Commun; 2023 Jan; 3(1):66-79. PubMed ID: 36968221
[TBL] [Abstract][Full Text] [Related]
11. Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance.
Muller YD; Ferreira LMR; Ronin E; Ho P; Nguyen V; Faleo G; Zhou Y; Lee K; Leung KK; Skartsis N; Kaul AM; Mulder A; Claas FHJ; Wells JA; Bluestone JA; Tang Q
Front Immunol; 2021; 12():686439. PubMed ID: 34616392
[TBL] [Abstract][Full Text] [Related]
12. Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope.
MacLachlan BJ; Dolton G; Papakyriakou A; Greenshields-Watson A; Mason GH; Schauenburg A; Besneux M; Szomolay B; Elliott T; Sewell AK; Gallimore A; Rizkallah P; Cole DK; Godkin A
J Biol Chem; 2019 Dec; 294(52):20246-20258. PubMed ID: 31619516
[TBL] [Abstract][Full Text] [Related]
13. CAR-J cells for antibody discovery and lead optimization of TCR-like immunoglobulins.
Jost C; Darowski D; Challier J; Pulko V; Hanisch LJ; Xu W; Mössner E; Bujotzek A; Klostermann S; Umana P; Kontermann RE; Klein C
MAbs; 2020; 12(1):1840709. PubMed ID: 33136521
[TBL] [Abstract][Full Text] [Related]
14. An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma.
Tian M; Cheuk AT; Wei JS; Abdelmaksoud A; Chou HC; Milewski D; Kelly MC; Song YK; Dower CM; Li N; Qin H; Kim YY; Wu JT; Wen X; Benzaoui M; Masih KE; Wu X; Zhang Z; Badr S; Taylor N; Croix BS; Ho M; Khan J
J Clin Invest; 2022 Aug; 132(16):. PubMed ID: 35852863
[TBL] [Abstract][Full Text] [Related]
15. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.
Liu X; Xu Y; Xiong W; Yin B; Huang Y; Chu J; Xing C; Qian C; Du Y; Duan T; Wang HY; Zhang N; Yu JS; An Z; Wang R
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338087
[TBL] [Abstract][Full Text] [Related]
16. Structural analysis of two HLA-DR-presented autoantigenic epitopes: crucial role of peripheral but not central peptide residues for T-cell receptor recognition.
De Oliveira DB; Harfouch-Hammoud E; Otto H; Papandreou NA; Stern LJ; Cohen H; Boehm BO; Bach J; Caillat-Zucman S; Walk T; Jung G; Eliopoulos E; Papadopoulos GK; van Endert PM
Mol Immunol; 2000 Oct; 37(14):813-25. PubMed ID: 11257303
[TBL] [Abstract][Full Text] [Related]
17. Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma.
Zhang C; Wang L; Zhang Q; Shen J; Huang X; Wang M; Huang Y; Chen J; Xu Y; Zhao W; Qi Y; Li Y; Ou Y; Yang Z; Qian C
Front Immunol; 2023; 14():1182409. PubMed ID: 37304295
[TBL] [Abstract][Full Text] [Related]
18. Nanobody-based CAR T cells targeting intracellular tumor antigens.
Li H; Zhong D; Luo H; Shi W; Xie S; Qiang H; Zhu L; Gao L; Liu J; Sun S; Ding Z; Yang X; Lu X
Biomed Pharmacother; 2022 Dec; 156():113919. PubMed ID: 36411612
[TBL] [Abstract][Full Text] [Related]
19. Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells.
Koristka S; Ziller-Walter P; Bergmann R; Arndt C; Feldmann A; Kegler A; Cartellieri M; Ehninger A; Ehninger G; Bornhäuser M; Bachmann MP
Cancer Immunol Immunother; 2019 Sep; 68(9):1401-1415. PubMed ID: 31414180
[TBL] [Abstract][Full Text] [Related]
20. Development of a T-cell receptor mimic antibody targeting a novel Wilms tumor 1-derived peptide and analysis of its specificity.
Kurosawa N; Midorikawa A; Ida K; Fudaba YW; Isobe M
Cancer Sci; 2020 Oct; 111(10):3516-3526. PubMed ID: 32770595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
